XNCR Xencor Inc. Company Short-Term Debt

Xencor - graphic logo of issuer XNCR

The price trajectory of Xencor, Inc. (XNCR) demonstrates a current indicator of 0.01. Financial stability is supported by prepayments from global corporations, which offsets cash flow gaps during risky trials of new drugs. The business is integrated into partners' research cycles via the XmAb system. Additional revenue is generated by licensing its proprietary platform, which allows for the scaling of antibody production without marketing expenses.

XNCR xencor.com Short-Term Debt (07/04/2022 - 10/31/2026)

Analytical breakdowns and data insights for company Xencor Inc. (XNCR)

- current quotes and average value forecast:
Price Chart Xencor|XNCR - Average Forecast Price
- market capitalization data:
Market Value Xencor, Inc.|XNCR - Total Company Value
- shareholders' equity book value data:
Net Assets per Single Share Xencor|XNCR - Total Stockholders' Equity|Market Capitalization to Book Value Ratio xencor.com|XNCR - Company Balance Sheet Assets
- company total debt and liquidity indicators:
Total Debt to Equity Ratio Xencor, Inc.|XNCR - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Xencor, Inc.|XNCR - Aggregate Debt Obligations|Debts to Book Capitalization Xencor, Inc.|XNCR - Long-Term Debt Volume|Company Short-Term Debt Xencor|Quick Liquidity xencor.com
- earnings and multiples data:
XNCR - Net Income
General company analysis:Xencor (XNCR)
Flagship merchandise of xencor.com

Xencor, Inc. (XNCR) bases its success on a unique antibody engineering platform and revenues from licensing agreements. By analyzing the short-term debt trend, an investor assesses the company's obligations with maturities of up to one year. This indicator measures current liquidity and the business's financial resilience to sudden shocks. For a biotech firm, this is critical when financing costly clinical phases. Monitoring the curve allows for the avoidance of overestimating risks or underestimating credit leverage.

Competitors of Xencor, Inc.

IBRX - Company Short-Term Debt|Short-Term Debt Immunocore Holdings|Janux Pharma (JANX) - Company Short-Term Debt|RCUS (Arcus Corp) - Company Short-Term Debt|Company Short-Term Debt Zymeworks Inc.|Short-Term Debt tangotx.com TNGX|Company Short-Term Debts IOVA|Immatics NV (IMTX) - Short-Term Indebtedness|Compass Bio - Company Current Liabilities|Replimune Inc. (REPL) - Short-Term Debt|LYEL: Company Current Liabilities|Company Short-Term Loans and Borrowings IPHA (innate-pharma.com)|PYXS: Company Short-Term Debts|CGEN - Short-Term Debt Volume|Company Short-Term Debt IO Biotech Corp|Company Current Liabilities Sutro Biopharma, Inc (STRO)|Company Short-Term Debt MiNK Therapeutics, Inc. (INKT)|Company Current Liabilities werewolftx.com HOWL|Immix Biopharma - Company Current Liabilities|Company Short-Term Debts alxoncology.com ALXO|CUE - Company Short-Term Debt|PDSB (PDS Biotechnology) - Company Short-Term Indebtedness|sonnetbio.com (SONN) - Company Short-Term Debt|Short-Term Debt MAIABiotech.com (MAIA)|Company Current Liabilities LIMN|LVTX - Short-Term Indebtedness|Company Current Liabilities NXTC (NextCure Corp)|Amount of Current Liabilities LPTX|Company Short-Term Debts INTS (Intensity Therapeutics, Inc.)|Company Short-Term Loans and Borrowings SNSE|Theriva Biologics - Company Short-Term Debts|Short-Term Debt Gritstone bio, Inc.|Kineta Bio (KA) - Company Short-Term Debt|NexImmune Corporation - Company Short-Term Loans and Borrowings|TSBX (Turnstone Biologics Corp) - Company Short-Term Debts|Company Short-Term Debts vaccinex.com|Company Short-Term Debt Harpoon Therapeutics, Inc. (HARP)